γ |
Rate of progression from the acute infection stage to chronic infection with CD4 ≥ 500 (year-1) |
4.80 |
|
[32] |
σ1 |
Rate of progression for ART-naive individuals from CD4 ≥ 500 to 350 ≤ CD4 < 500 (year-1) |
1.35 |
|
[17] |
σ2 |
Rate of progression for ART-naive individuals from 350 ≤ CD4 < 500 to 200 ≤ CD4 < 350 (year-1) |
0.33 |
|
[17] |
σ3 |
Rate of progression for ART-naive individuals from 200 ≤ CD4 < 350 to CD4 < 200 (year-1) |
0.27 |
|
[17] |
c |
Mean number of partners per year |
2.3 |
|
[33] |
κ |
Proportion of partnerships in which condoms are used |
45.9% |
|
[34] |
ν |
Efficacy of condoms in reducing transmissibility in a partnership |
78% |
|
[31, 37, 38] |
ω |
Efficacy of ART in reducing HIV transmissibility |
92% |
50–100% |
[28] |
θ |
ART dropout rate (year-1) |
0.10 |
0.05–0.20 |
[12, 13, 35, 36] |
μ |
Inverse of the sexual life expectancy (year-1) |
1/ 50 = 0.02 |
|
[39] |
η |
Efficacy of ART in reducing HIV-attributable mortality |
90% |
|
[30] |
αAc |
Additional mortality attributable to HIV infection during acute infection (year-1) |
0.00 |
|
Assumed negligible |
αI1 |
Additional mortality attributable to HIV infection in ART-naive individuals with CD4 ≥ 500 (year-1) |
0.007 |
|
[29] |
αI2 |
Additional mortality attributable to HIV infection in ART-naive individuals with 350 ≤ CD4 < 500 (year-1) |
0.006 |
|
[29] |
αI3 |
Additional mortality attributable to HIV infection in ART-naive individuals with 200 ≤ CD4 < 350 (year-1) |
0.007 |
|
[29] |
αI4 |
Additional mortality attributable to HIV infection in ART-naive individuals with CD4 < 200 (year-1) |
0.262 |
|
[29] |
RRAc |
Relative infectivity of individuals in the acute phase of infection vs. chronic ART-naive CD4 ≥ 350 |
11.7 |
|
[32] |
RRI3 |
Relative infectivity of infected ART-naive individuals with 200 ≤ CD4 < 350 vs. CD4 ≥ 350 |
1.6 |
|
[28] |
RRI4 |
Relative infectivity of infected ART-naive individuals with CD4 < 200 vs. CD4 ≥ 350 |
5.0 |
|
[28] |